

Phase III Trial of the Mosaic Vaccine

Mosaico (HPX3002/HVTN 706) is the Phase III efficacy trial starting in 2019 among 3,800 MSM and transgender people across 55 trial sites in the following countries: Argentina, Brazil, Italy, Mexico, Peru, Poland, Spain and the US⁹. Under investigation is the heterologous vaccine regimen using Ad26. Mos4.HIV and Clade C and Mosaic gp140. This is a slightly revised regimen—in that it has the added Mosaic gp140 to the boost doses—from the one being tested in the Phase IIb Imbokodo (HPX2008/HVTN 705) proof of concept trial in sub-Saharan Africa.

A mosaic-based vaccine regimen is designed to create immune responses to multiple clades and may offer one strategy for overcoming the constantly mutating HIV genes, as well as conferring broader geographic immunity. Mosaico is sponsored by Janssen Vaccines & Prevention B.V. and is estimated to end in June 2023⁹.